BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 31027693)

  • 21. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: clinical outcomes from a National Patient Registry.
    Davis JN; Medbery C; Sharma S; Perry D; Pablo J; D'Ambrosio DJ; McKellar H; Kimsey FC; Chomiak PN; Mahadevan A
    J Radiat Oncol; 2015; 4(1):55-63. PubMed ID: 25774243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): Extremely safe and effective.
    Kreinbrink P; Blumenfeld P; Tolekidis G; Sen N; Sher D; Marwaha G
    J Geriatr Oncol; 2017 Sep; 8(5):351-355. PubMed ID: 28739159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions.
    Ding M; Zollinger W; Ebeling R; Heard D; Posey R
    J Appl Clin Med Phys; 2018 Nov; 19(6):226-233. PubMed ID: 30216639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy.
    Shiue K; Cerra-Franco A; Shapiro R; Estabrook N; Mannina EM; Deig CR; Althouse S; Liu S; Wan J; Zang Y; Agrawal N; Ioannides P; Liu Y; Zhang C; DesRosiers C; Bartlett G; Ewing M; Langer MP; Watson G; Zellars R; Kong FM; Lautenschlaeger T
    J Thorac Oncol; 2018 Oct; 13(10):1549-1559. PubMed ID: 29959060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Single- and Five-fraction Regimens of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-small-cell Lung Cancer: A Two-institution Propensity-matched Analysis.
    Cummings MA; Ma SJ; Hermann G; Serra L; Syed Y; Malhotra HK; Chen Y; Milano MT; Gomez-Suescun JA; Singh DP; Singh AK
    Clin Lung Cancer; 2018 Nov; 19(6):511-517. PubMed ID: 30131257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic body radiation therapy for stage I non-small cell lung cancer: The importance of treatment planning algorithm and evaluation of a tumor control probability model.
    Ohri N; Tomé W; Kalnicki S; Garg M
    Pract Radiat Oncol; 2018; 8(2):e33-e39. PubMed ID: 29233523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
    Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic radiotherapy (SBRT) as a sole or salvage therapy in non-small cell lung cancer patients.
    Dworzecki T; Idasiak A; Syguła D; Dworzecka U; Suwiński R
    Neoplasma; 2012; 59(1):114-20. PubMed ID: 22103905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer.
    Ma SJ; Serra LM; Syed YA; Hermann GM; Gomez-Suescun JA; Singh AK
    Clin Lung Cancer; 2018 Mar; 19(2):e235-e240. PubMed ID: 29153897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognosis Analysis of Early-stage Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy].
    Yu L; Li J; Gao M; Wang X; Bai H; Guan Y; Yuan Z
    Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):274-280. PubMed ID: 37183642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
    Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
    Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.
    Repka MC; Aghdam N; Kataria SK; Campbell L; Suy S; Collins SP; Anderson E; Lischalk JW; Collins BT
    Radiat Oncol; 2017 Oct; 12(1):162. PubMed ID: 29052514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis.
    Buergy D; Würschmidt F; Gkika E; Hörner-Rieber J; Knippen S; Gerum S; Balermpas P; Henkenberens C; Voglhuber T; Kornhuber C; Barczyk S; Röper B; Rashid A; Blanck O; Wittig A; Herold HU; Brunner TB; Klement RJ; Kahl KH; Ciernik IF; Ottinger A; Izaguirre V; Putz F; König L; Hoffmann M; Combs SE; Guckenberger M; Boda-Heggemann J
    Int J Cancer; 2021 Jul; 149(2):358-370. PubMed ID: 33682927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.
    Horne ZD; Richman AH; Dohopolski MJ; Clump DA; Burton SA; Heron DE
    Lung Cancer; 2018 Jan; 115():1-4. PubMed ID: 29290248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study.
    Miyakawa A; Shibamoto Y; Baba F; Manabe Y; Murai T; Sugie C; Yanagi T; Takaoka T
    Radiat Oncol; 2017 Sep; 12(1):152. PubMed ID: 28893300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy.
    Iocolano M; Wild AT; Hannum M; Zhang Z; Simone CB; Gelblum D; Wu AJ; Rimner A; Shepherd AF
    Acta Oncol; 2020 Feb; 59(2):164-170. PubMed ID: 31608751
    [No Abstract]   [Full Text] [Related]  

  • 37. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes in stage I non-small cell lung cancer following the introduction of stereotactic body radiotherapy in Alberta - A population-based study.
    Liu HW; Gabos Z; Ghosh S; Roberts B; Lau H; Kerba M
    Radiother Oncol; 2015 Oct; 117(1):71-6. PubMed ID: 26349589
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prior Treatment for Non-small Cell Lung Cancer Is Associated With Improved Survival in Patients who Undergo Definitive Stereotactic Body Radiation Therapy for a Subsequent Lung Malignancy: A Retrospective Multivariate and Matched Pair Analysis.
    Farrugia MK; Jun Ma S; Hennon MW; Nwogu CE; Dexter EU; Picone AL; Demmy TL; Gomez-Suescun JA; Fung-Kee-Fung S; Yendamuri SS; Singh AK
    Am J Clin Oncol; 2021 Jan; 44(1):18-23. PubMed ID: 33264123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer.
    Parks J; Kloecker G; Woo S; Dunlap NE
    Am J Clin Oncol; 2016 Apr; 39(2):147-53. PubMed ID: 24457534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.